Hester Biosciences has reduced its subsidiary Hester Africa's loan amount to $5M following amended terms, with the Gates Foundation forgoing interest payments. This move is expected to enhance the subsidiary's liquidity and ease debt servicing due to a relief on interest repayments.

Hester Biosciences conducted its Q4 FY26 earnings discussion on May 15, 2026, facilitated by ICICI Securities. The event was officially announced by the call operator.

Hester Biosciences saw a 22% boost in Q4 revenues, primarily attributed to success in the Poultry Healthcare sector. The impressive 174% increase in profit after tax (PAT) can be credited to successful new vaccine launches.

Hester Biosciences' Q4 net profit surged significantly, reaching ₹15.9 crore compared to ₹1.2 crore in the same period last year. The company also reported a 22% increase in revenue to ₹100 crore and an impressive 78% rise in EBITDA, with a 34.2% margin.

Hester Biosciences is offering a Rs 11/share dividend, indicating robust investor rewards due to the company's impressive business results.

Hester Biosciences reported a significant 22% increase in Q4 revenue, reaching Rs. 1 billion, demonstrating notable growth compared to last year's figure of Rs. 819 million.